SCHEMBL2651804

SCHEMBL2651804

O=C(O)C(CC1CCCC1)c1ccc(C#CC2(O)CCCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 2/20 0.42
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP12 P39900 1/20 0.40
KDM4E B2RXH2 1/20 0.39
XBP1 P17861 1/20 0.39
MAPK1 P28482 1/20 0.38
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
NR2F2 P24468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651162 0.86 ALDH1A1 (0.46) ALDH1A1L3MBTL1LMNAMAPTPOLB
SCHEMBL2650870 0.79 MMP2 (0.44) L3MBTL1LMNAMMP2MMP9MMP12
SCHEMBL2651877 0.78 GCK (0.61) POLB
SCHEMBL2651230 0.77 MMP2 (0.41) L3MBTL1POLBMMP2MMP9MMP12
SCHEMBL2645029 0.77 TSHR (0.41) L3MBTL1MAPTKMT2AMMP2MMP9
SCHEMBL2651504 0.76 MMP2 (0.44) L3MBTL1MMP2MMP9MMP12NPC1
SCHEMBL2651218 0.75 ALDH1A1 (0.45) ALDH1A1L3MBTL1MMP2MMP9MMP12
SCHEMBL2651839 0.75 CYP2D6 (0.45) MMP2MMP9MMP12FFAR1
SCHEMBL2653001 0.75 MMP2 (0.41) LMNAPOLBMMP2MMP9MMP12
SCHEMBL10379945 0.74 DPEP1 (0.45) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1282612-B1 ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
EP-1282612-A2 ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-12 EP disclosed
US-6388071-B2 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-05-14 US disclosed
US-20010053851-A1 Alkynyl phenyl heteroaromatic glucokinase activators HOFFMAN-LA ROCHE INC. 2001-12-20 US disclosed
WO-2001083465-A2 ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053851-A1 Alkynyl phenyl heteroaromatic glucokinase activators GCK, GCKR, HK2 ALDH1A1 1969/4885L3MBTL1 2823/4885LMNA 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.